Literature DB >> 8622766

Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2.

J Zhang1, S Hagopian-Donaldson, G Serbedzija, J Elsemore, D Plehn-Dujowich, A P McMahon, R A Flavell, T Williams.   

Abstract

The retinoic acid-inducible transcription factor AP-2 is expressed in epithelial and neural crest cell lineages during murine development. AP-2 can regulate neural and epithelial gene transcription, and is associated with overexpression of c-erbB-2 in human breast-cancer cell lines. To ascertain the importance of AP-2 for normal development, we have derived mice containing a homozygous disruption of the AP-2 gene. These AP-2-null mice have multiple congenital defects and die at birth. In particular, the AP-2 knockout mice exhibit anencephaly, craniofacial defects and thoraco-abdominoschisis. Skeletal defects occur in the head and trunk region, where many bones are deformed or absent. Analysis of these mice earlier in embryogenesis indicates a failure of cranial neural-tube closure and defects in cranial ganglia development. We have shown that AP-2 is a fundamental regulator of mammalian craniofacial development.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8622766     DOI: 10.1038/381238a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  173 in total

1.  Structure and expression of the human p68 RNA helicase gene.

Authors:  O G Rössler; P Hloch; N Schütz; T Weitzenegger; H Stahl
Journal:  Nucleic Acids Res       Date:  2000-02-15       Impact factor: 16.971

2.  Novel TFAP2B mutations that cause Char syndrome provide a genotype-phenotype correlation.

Authors:  F Zhao; C G Weismann; M Satoda; M E Pierpont; E Sweeney; E M Thompson; B D Gelb
Journal:  Am J Hum Genet       Date:  2001-08-14       Impact factor: 11.025

3.  Transcriptional activation by AP-2alpha is modulated by the oncogene DEK.

Authors:  Mónica Campillos; Miguel Angel García; Fernando Valdivieso; Jesús Vázquez
Journal:  Nucleic Acids Res       Date:  2003-03-01       Impact factor: 16.971

4.  Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2beta.

Authors:  M Moser; A Pscherer; C Roth; J Becker; G Mücher; K Zerres; C Dixkens; J Weis; L Guay-Woodford; R Buettner; R Fässler
Journal:  Genes Dev       Date:  1997-08-01       Impact factor: 11.361

5.  FOXD1 Duplication Causes Branchial Defects and Interacts with the TFAP2A Gene Implicated in the Branchio-Oculo-Facial Syndrome in Causing Eye Effects in Zebrafish.

Authors:  I Balikova; K Devriendt; J-P Fryns; J R Vermeesch
Journal:  Mol Syndromol       Date:  2011-05-18

6.  Transcription factor AP-2alpha is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor alpha-induced apoptosis in breast cancer cells.

Authors:  O Nyormoi; Z Wang; D Doan; M Ruiz; D McConkey; M Bar-Eli
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

7.  Complementary expression of AP-2 and AP-2rep in ectodermal derivatives of Xenopus embryos.

Authors:  Masanori Gotoh; Yumi Izutsu; Mitsugu Maéno
Journal:  Dev Genes Evol       Date:  2003-05-17       Impact factor: 0.900

8.  Inhibition of neural crest formation by Kctd15 involves regulation of transcription factor AP-2.

Authors:  Valeria E Zarelli; Igor B Dawid
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

9.  Developmental regulation of gonadotropin-releasing hormone gene expression by the MSX and DLX homeodomain protein families.

Authors:  Marjory L Givens; Naama Rave-Harel; Vinodha D Goonewardena; Reiko Kurotani; Sara E Berdy; Christo H Swan; John L R Rubenstein; Benoit Robert; Pamela L Mellon
Journal:  J Biol Chem       Date:  2005-03-01       Impact factor: 5.157

10.  Mutations in the SOD2 promoter reveal a molecular basis for an activating protein 2-dependent dysregulation of manganese superoxide dismutase expression in cancer cells.

Authors:  Yong Xu; Fang Fang; Sanjit K Dhar; Antonio Bosch; William H St Clair; Edward J Kasarskis; Daret K St Clair
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.